» Articles » PMID: 32197832

Continuing the Search for a Hormonal Male Contraceptive

Overview
Publisher Elsevier
Date 2020 Mar 22
PMID 32197832
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

This chapter discusses the mechanisms of action of hormonal male contraception, which suppresses the hypothalamic-pituitary-testis axis. When the intratesticular concentration of testosterone is subsequently suppressed to adequately low concentrations, spermatogenesis is arrested. Androgens are a necessary hormonal male contraceptive component because they not only suppress the hypothalamic-pituitary-testis axis, but also provide the male hormone necessary to maintain peripheral androgen functions. Past studies using testosterone alone and testosterone combined with progestins demonstrated contraceptive efficacy in the female partner at rates similar to combined hormonal female methods. Newer hormonal male contraceptive formulations and the alternative routes of administration are discussed, along with potential barriers, challenges, and opportunities for hormonal male contraceptive development. Novel methods that are safe, effective, reversible, user-friendly, and coitus-independent are intrinsic to equitably meet the various needs and limitations of an increasingly diverse population.

Citing Articles

Male contraception development: monitoring effective spermatogenesis suppression utilizing a user-controlled sperm concentration test compared with standard semen analysis.

Lue Y, Swerdloff R, Pak Y, Nguyen B, Yuen F, Liu P Fertil Steril. 2022; 119(2):208-217.

PMID: 36347310 PMC: 9898087. DOI: 10.1016/j.fertnstert.2022.11.002.


Knowledge and Perception Regarding the Development and Acceptability of Male Contraceptives Among Pharmacists: A Mixed Sequential Method.

Barakat M, Thiab S, Thiab S, Al-Qudah R, Akour A Am J Mens Health. 2022; 16(1):15579883221074855.

PMID: 35135388 PMC: 8832602. DOI: 10.1177/15579883221074855.


Blockade of GRTH/DDX25 Phosphorylation by Cyclic Peptides Provides an Avenue for Developing a Nonhormonal Male Contraceptive.

Raju M, Kavarthapu R, Anbazhagan R, Hassan S, Dufau M J Med Chem. 2021; 64(19):14715-14727.

PMID: 34601876 PMC: 9446413. DOI: 10.1021/acs.jmedchem.1c01201.

References
1.
Liu P, Swerdloff R, Christenson P, Handelsman D, Wang C . Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006; 367(9520):1412-20. DOI: 10.1016/S0140-6736(06)68614-5. View

2.
Gu Y, Wang X, Xu D, Peng L, Cheng L, Huang M . A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003; 88(2):562-8. DOI: 10.1210/jc.2002-020447. View

3.
Behre H, Zitzmann M, Anderson R, Handelsman D, Lestari S, McLachlan R . Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. J Clin Endocrinol Metab. 2016; 101(12):4779-4788. DOI: 10.1210/jc.2016-2141. View

4.
Anawalt B, Roth M, Ceponis J, Surampudi V, Amory J, Swerdloff R . Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology. 2019; 7(6):878-887. PMC: 6768743. DOI: 10.1111/andr.12603. View

5.
Dorman E, Bishai D . Demand for male contraception. Expert Rev Pharmacoecon Outcomes Res. 2012; 12(5):605-13. DOI: 10.1586/erp.12.52. View